QIAGEN Reports the US FDA Clearance of QIAstat-Dx BCID GPF Plus AMR Panel for Bloodstream Infection Syndromic Testing

Shots:

• The US FDA has granted clearance to QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infection testing 
• The panel identifies 20 gram-positive bacterial & fungal pathogen targets & 10 antimicrobial resistance markers, delivering results in ~1 hour to support rapid clinical decision-making & antimicrobial stewardship
• Clearance supports QIAGEN’s expansion of its US bloodstream infection testing portfolio. Its complementary QIAstat-Dx BCID GN Plus AMR Panel, which detects gram-negative pathogens & genetic antimicrobial resistance markers, remains under FDA review

Ref:  Businesswire  |  Image: QIAGEN  |  Press Release

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com